Search

Displaying results 9161 - 9170 of 10000 in total
  1. Drug

    Dasolampanel etibutil

    go.drugbank.com/drugs/DB12049
    Investigational

    Dasolampanel etibutil has been used in trials studying the treatment of Diabetic Neuropathy, Painful.

  2. Drug

    Rislenemdaz

    go.drugbank.com/drugs/DB12063
    Investigational

    Mk 0657 has been used in trials studying the treatment of Major Depressive Disorder.

    Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitors
  3. Drug

    Avoralstat

    go.drugbank.com/drugs/DB12120
    Investigational

    Avoralstat has been used in trials studying the prevention of HAE and Hereditary Angioedema.

  4. Drug

    Balicatib

    go.drugbank.com/drugs/DB12239
    Investigational

    Balicatib has been used in trials studying the treatment of Osteoporosis and Knee Osteoarthritis.

  5. Drug

    Carmegliptin

    go.drugbank.com/drugs/DB12268
    Investigational

    Carmegliptin has been used in trials studying the treatment of Diabetes Mellitus Type 2.

  6. Drug

    Muscimol

    go.drugbank.com/drugs/DB12458
    Investigational

    Muscimol has been used in trials studying the treatment of Epilepsy and Parkinson's Disease.

  7. Drug

    Letrazuril

    go.drugbank.com/drugs/DB12663
    Investigational

    Letrazuril has been used in trials studying the treatment of HIV Infections and Cryptosporidiosis.

  8. Drug

    Farampator

    go.drugbank.com/drugs/DB15012
    Investigational

    Farampator is under investigation in clinical trial NCT00113022 (Org 24448 to Treat Major Depression).

  9. Drug

    Fluciclovine

    go.drugbank.com/drugs/DB15237
    Investigational

    Fluciclovine is under investigation in clinical trial NCT03036943 (Fluciclovine (18F) Imaging of Breast Cancer).

  10. Drug

    CIGB-258 peptide

    go.drugbank.com/drugs/DB15809
    Experimental

    As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens